Despite FDA’s postponement of most facility inspections, the pharma manufacturing industry should be prepared for heightened scrutiny as this crisis develops
Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines